NovaBay Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- NovaBay Pharmaceuticals's estimated annual revenue is currently $7.1M per year.
- NovaBay Pharmaceuticals received $6.0M in venture funding in February 2018.
- NovaBay Pharmaceuticals's estimated revenue per employee is $100,500
- NovaBay Pharmaceuticals's total funding is $52.7M.
Employee Data
- NovaBay Pharmaceuticals has 71 Employees.
- NovaBay Pharmaceuticals grew their employee count by -4% last year.
NovaBay Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Director Ecommerce | Reveal Email/Phone |
3 | Interim Chief Financial Officer | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | Manager, Drug Production Development and Manufacturing | Reveal Email/Phone |
6 | Marketing Manager | Reveal Email/Phone |
7 | Quality Assurance Manager | Reveal Email/Phone |
8 | Digital Advertising Manager | Reveal Email/Phone |
9 | Sr. Manager, Digital Marketing | Reveal Email/Phone |
10 | Regional Market Manager / Mid-Atlantic, Southeast, Southwest, West Coast | Reveal Email/Phone |
NovaBay Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX family of products, led by AVENOVA for the eye care market, NEUTROPHASE® for wound care, and CELLERX for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million. NovaBay is gaining market traction with AVENOVA through its 35-medical direct sales representatives under veteran leadership. AVENOVA is available for order in 90% of all pharmacies across the U.S. through distribution agreements with AmerisourceBergen, Cardinal Health and McKesson. www.novabay.com. www.Avenova.com www.neutrophase.com www.celerex.com
keywords:Biotechnology,Healthcare,Household & Personal Products,Personal Products,Pharmaceuticals
$52.7M
Total Funding
71
Number of Employees
$7.1M
Revenue (est)
-4%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NovaBay Pharmaceuticals News
NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com. Posted by admin on Apr 19th, 2022.
NovaBay Pharma (NBY -2.2%) posted lower-than-expected Q4 revenue; Net product revenue for the quarter rose 40% to $2.6 million,...
--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31,...
Other Companies in Emeryville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $27M | 75 | 19% | N/A |
#2 | $18.5M | 76 | 7% | N/A |
#3 | $24.9M | 77 | 8% | N/A |
#4 | $12.2M | 79 | 3% | N/A |
#5 | $84M | 82 | -61% | $272.6M |
NovaBay Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-08-24 | $2.4M | Undisclosed | Maxim Group LLC | Article |
| 2011-06-30 | $5.2M | Undisclosed | Article | |
| 2012-11-06 | $1.5M | Undisclosed | Pioneer Pharma (Singapore) Pte | Article |
| 2014-03-21 | $6.7M | Undisclosed | Article | |
| 2016-01-08 | $3.0M | Undisclosed | China Kington Asset Management Co. Ltd | Article |
| 2016-03-01 | $2.8M | Undisclosed | Article | |
| 2016-05-24 | $7.8M | Undisclosed | Article | |
| 2016-08-03 | $4.0M | Undisclosed | Article | |
| 2018-02-13 | $6.0M | Undisclosed | OP Financial Investments Limited | Article |